New Taipei City, Taiwan – May 22, 2026
Caliway Biopharmaceuticals has announced a major milestone for its innovative injectable fat-reduction therapy CBL-514, after receiving U.S. FDA clearance for the Investigational New Drug (IND) application for CBL-0302 (SUPREME-02), the company’s second global pivotal Phase 3 clinical study. The regulatory advancement, combined with newly approved Asia-Pacific clinical expansion plans, positions Caliway to accelerate the worldwide development and commercialization of its first-in-class aesthetic medicine candidate.
FDA Clears Second Global Phase 3 Trial for CBL-514
The FDA clearance marks a significant regulatory achievement for Caliway’s non-surgical localized fat reduction therapy. The IND successfully completed the FDA’s 30-day review process, allowing the company to move forward with patient enrollment for the multinational Phase 3 trial. The study, known as CBL-0302, will evaluate the efficacy, safety, and tolerability of CBL-514 injections in approximately 320 participants across the United States, Canada, and Australia.
The clinical trial uses a randomized, double-blind, placebo-controlled design, considered the gold standard for evaluating therapeutic performance. Caliway confirmed that both pivotal Phase 3 studies, CBL-0301 and CBL-0302, are expected to begin enrollment soon, with topline data projected in 2027 to support a future New Drug Application (NDA) submission. The company has also submitted related clinical study applications to Health Canada and Australian authorities to strengthen the global regulatory pathway for CBL-514.
MRI-Based Endpoints Aim to Redefine Aesthetic Medicine Standards
Advertisement
One of the most notable aspects of the CBL-0302 study is the inclusion of objective MRI-based fat volume measurements as a primary efficacy endpoint. According to Caliway, this differentiates CBL-514 from many currently available aesthetic drugs and devices that primarily rely on subjective appearance improvement assessments.
The trial’s co-primary endpoints include abdominal subcutaneous fat volume reduction measured by MRI and patient-assessed improvement using the Patient-Reported Abdominal Fat Rating Scale (PR-AFRS). Caliway stated that these endpoints were strongly supported by data from its previously completed Phase 2b studies, CBL-0204 and CBL-0205, which successfully achieved all primary efficacy and safety goals.
Industry analysts view this evidence-based imaging approach as a potentially transformative development in the rapidly growing aesthetic medicine market, where demand for minimally invasive body contouring therapies continues to rise worldwide. By emphasizing quantifiable fat reduction rather than cosmetic appearance alone, Caliway aims to establish stronger scientific credibility and broader medical acceptance for CBL-514.
Asia-Pacific Expansion Strengthens Dual-Track Clinical Strategy
In parallel with its global Phase 3 program, Caliway is also aggressively expanding its regional clinical development strategy across Asia-Pacific markets. The company announced that both the Taiwan Food and Drug Administration (TFDA) and Australia’s Human Research Ethics Committee (HREC) approved the CBL-0206 Phase 2 study, further supporting Caliway’s “global and regional parallel” development model.
The Asia-Pacific study is expected to enroll approximately 250 participants in Taiwan and Australia. The two-stage, randomized placebo-controlled study will gather additional efficacy and safety data specifically focused on Asian populations, expanding the demographic diversity of the overall clinical database. Caliway believes this strategy will strengthen future regulatory submissions, regional commercialization efforts, and international licensing opportunities.
The company also revealed plans to submit a Phase 3 clinical study application in China during the second half of 2026, highlighting its ambition to establish a strong presence in both Western and Asian aesthetic medicine markets simultaneously.
CBL-514 is currently being developed as the world’s first injectable lipolysis drug designed to induce adipocyte apoptosis for targeted fat reduction without identified systemic safety risks. To date, Caliway reports that 10 clinical trials involving 544 participants have been completed successfully, with all major efficacy and safety endpoints achieved.
Source: Caliway Biopharmaceuticals press release
